CPRX — Catalyst Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapSuper Stock

Annual income statement for Catalyst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	119	141	214	398	492
Cost of Revenue
Gross Profit	102	119	180	346	423
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	77.8	88.4	112	311	297
Operating Profit	41.3	52.4	102	86.8	195
Other Net Non Operating Costs
Net Income Before Taxes	41.9	52.7	105	94.5	216
Provision for Income Taxes
Net Income After Taxes	75	39.5	83.1	71.4	164
Net Income Before Extraordinary Items
Net Income	75	39.5	83.1	71.4	164
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	75	39.5	83.1	71.4	164
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.706	0.366	0.746	0.628	1.31